Daniel G. Anderson

Founder & Scientific Advisor at Sigilon Therapeutics

Daniel G. Anderson, Ph.D., is a co-founder of Sigilon and has served as a member of our board of directors since 2016. Dr. Anderson is a leading researcher in the field of nanotherapeutics and

biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

Timeline

  • Founder & Scientific Advisor

    Current role